Aprea Therapeutics, Inc. (APRE) 股票分析

公司概述

Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise dedicated to the development and commercialization of novel synthetic lethality-based cancer therapeutics that specifically target DNA damage response pathways. The company's primary focus lies in creating APR-1051, an orally bioavailable small-molecule inhibitor designed to address critical oncological challenges through its lead product candidates. This entity functions within the Healthcare sector, specifically categorized under the Biotechnology industry, positioning it as a specialized player in the pharmaceutical research and development landscape. In terms of scale, Aprea Therapeutics maintains a market capitalization of $8.41M and employs 8 individuals, while reporting a trailing twelve-month revenue of $285,759. These figures indicate that the company is a micro-cap entity with a very small revenue base relative to its market valuation, suggesting a high reliance on future clinical milestones and successful product commercialization to bridge the current valuation gap with tangible financial performance.

财务健康

The company reported a trailing twelve-month revenue of $285,759, yet simultaneously incurred a net income of $-12,599,569 and an EBITDA of $-13,212,121. The substantial disparity between the nominal revenue and the multi-million dollar net loss reveals a cost structure dominated by significant operating expenses, likely driven by research and development costs inherent to the clinical-stage biotechnology model. Free cash flow stands at $-8,564,504, which indicates that the company is currently burning cash to fund its operations and development pipeline rather than generating surplus liquidity. Analyzing the margin profile, the gross margin is recorded at 0.0%, while the operating margin is an extreme -79205.7% and the profit margin is 0.0%; these negative or negligible margins highlight the intense capital intensity and current inability to achieve profitability typical for early-stage drug developers. Regarding capital structure, the company holds $14.60M in cash against $0 in debt, resulting in a debt-to-equity ratio that is listed as N/A, which suggests a highly conservative balance sheet with no interest-bearing liabilities constraining its financial flexibility. The current ratio of 5.63 indicates a robust short-term liquidity position, providing ample coverage for current liabilities and ensuring the company can meet its immediate financial obligations without difficulty. Return on Equity is -74.6% and Return on Assets is -41.4%, metrics that reveal the company is currently diluting shareholder value and utilizing assets inefficiently in terms of generating positive returns, reflecting the pre-revenue nature of its business model.

估值评估

The trailing twelve-month P/E ratio is N/A due to the lack of positive earnings, whereas the forward P/E is listed at -1.11, implying that the market expects a return to profitability or is valuing the company based on future earnings potential that has not yet materialized. The price-to-book ratio stands at 0.48, indicating that the market values the company at less than its book value, which often reflects investor skepticism regarding the recoverability of assets in a pre-commercialization context. Alternative valuation metrics show a price-to-sales ratio of 29.42 and an EV/EBITDA of 0.41, suggesting that the stock is priced at a significant premium relative to its sales revenue, while the low EV/EBITDA multiple reflects the negative earnings reality of the current stage. The 52-week high for the stock is $2.22 and the 52-week low is $0.55; assuming a current price context within this range, the stock trades at a position that reflects high volatility and sensitivity to biotech sector sentiment, specifically hovering between these established bounds. The beta value is 1.57, which indicates that the stock's price volatility is significantly higher than the broader market, meaning that Aprea Therapeutics experiences amplified price swings relative to general market movements.

Growth & Income

Revenue growth year-over-year has declined by -98.4%, while earnings growth is N/A due to negative earnings; this implies that the company is not experiencing organic revenue expansion and is likely facing challenges in scaling its sales or maintaining consistent income streams. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, which is 0.0%, indicating that all available resources are being retained and reinvested into growth initiatives rather than distributed to shareholders. This reinvestment strategy is typical for clinical-stage biotechs that prioritize funding research and development over shareholder returns. Overall, the growth and income profile of Aprea Therapeutics is characterized by significant revenue contraction, a complete absence of dividend income, and a reliance on retained earnings to sustain operations until potential future commercialization events can generate positive cash flows.